<DOC>
	<DOC>NCT00808405</DOC>
	<brief_summary>To examine the time to healing of genital lesion and duration of herpes simplex virus (HSV) shedding from genetic ulcer disease (GUD) among 90 HIV-negative African women who have a history of GUD and are HSV-2 seropositive and HIV-1 seronegative randomized in a 2:1 ratio to receive episodic acyclovir 400mg orally three times daily or matching placebo three times daily for 5 days and who are followed for a total of 13 days.</brief_summary>
	<brief_title>GUD Clinical and Virologic Response to Acyclovir in HIV Negative African Women</brief_title>
	<detailed_description />
	<mesh_term>Herpes Genitalis</mesh_term>
	<mesh_term>Acyclovir</mesh_term>
	<criteria>HIV negative as determined by concordant rapid testing HSV2 seropositive (Focus HerpeSelect &gt;3.4) At least one prior occurrence of GUD 1850 years of age Current use, or use w/in past 7 days of acyclovir, valacyclovir, or famciclovir Prior hypersensitivity &amp;/or allergic reaction to acyclovir Use of probenicid Current use, or use within past 28 days, of an investigational agent Currently pregnant or nursing Currently plan to become pregnant during next 3 months Any condition that will interfere with successful completion of study procedures</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>herpes simplex virus</keyword>
	<keyword>acyclovir</keyword>
	<keyword>HSV shedding</keyword>
	<keyword>women</keyword>
	<keyword>Africa</keyword>
</DOC>